DADC
PTCT icon

D.A. Davidson & Co’s PTC Therapeutics PTCT Stock Holding History

D.A. Davidson & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200
Closed -$5K – 2266
2015
Q3 		$5K Hold
200
– – ﹤0.01% 2007
2015
Q2 		$9K Buy
+200
New +$11.7K ﹤0.01% 1898

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

D.A. Davidson & Co's PTCT Position: Q4 2015 in Review

D.A. Davidson & Co sold out of PTC Therapeutics (PTCT) in Q4 2015, closing a stake of 200 shares — an estimated $5K sold.

D.A. Davidson & Co first reported a position in PTCT in Q2 2015 and held it in 2 quarters. The position peaked at $9K in Q2 2015. 141 funds tracked by Wall St. Rank hold PTCT as of Q4 2015.

  • D.A. Davidson & Co reported no remaining PTC Therapeutics position as of Q4 2015 after selling out during the quarter.
  • D.A. Davidson & Co sold 200 PTC Therapeutics shares in Q4 2015, an estimated $5K.
  • D.A. Davidson & Co first reported a position in PTC Therapeutics in Q2 2015 and held it in 2 quarters.
  • D.A. Davidson & Co's PTC Therapeutics position peaked at $9K in Q2 2015.
  • 141 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2015.

Based on D.A. Davidson & Co's 13F filing for Q4 2015, filed 12 Feb 2016.